<DOC>
	<DOCNO>NCT02594098</DOCNO>
	<brief_summary>Atopic Dermatitis , also know atopic eczema , eczema , common skin disease affect male female age , often start childhood . Recent study show least 4-7 % adults 15-25 % child affect , one third patient severe disease . It result itchy , red , swollen , cracked skin . Scratching worsens symptoms cause skin become thickened time . Patients atopic dermatitis increase risk skin infection , many also develop hay fever asthma . Atopic dermatitis cause significant distress patient family . In study , aim ass effect new treatment call secukinumab patient atopic dermatitis . A total 30 patient include study , run total 52 week .</brief_summary>
	<brief_title>Secukinumab Treatment Atopic Dermatitis</brief_title>
	<detailed_description>This randomize , double-blind , pilot study total 44 subject AD ( 22 intrinsic 22 extrinsic AD ) consist 2 phase . Subjects randomize ( 2:1 ) either receive secukinumab 300 mg placebo via subcutaneous injection use 2 prefilled syrinx .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject least 18 year age If female , subject pregnant nursing Subject able provide write informed consent comply requirement study protocol . Chronic ( &gt; 6 month ) atopic dermatitis ( intrinsic disease IgE level 200 , extrinsic disease IgE level 200 ) . Moderate severe AD ( SCORAD index ≥25 , IGA index≥3 ) . Subjects woman childbearing potential must negative urine pregnancy test screening must practice adequate , medically acceptable method birth control least 30 day Day 0 least 6 month last study drug administration . Acceptable method birth control include intrauterine device ( IUD ) ; oral , transdermal , implanted inject hormonal contraceptive ( must initiate least 1 month enter study ) ; tubal ligation ; abstinence barrier method spermicide . Otherwise , childbearing potential , subject must : sterile vasectomized partner ; hysterectomy , bilateral oophorectomy clinically diagnose infertile ; menopausal state least year . Tuberculin purify protein derivative ( PPD ) QuantiFERON TBGold test ( QFT ) negative time screening , patient history positive PPD QuantiFERON , he/she complete appropriate prophylaxis . Subject judge good general health determine principal investigator base upon result medical history , laboratory profile , physical examination . Patients stable chronic asthma , treat inhaled corticosteroid , allow participate . Male female subject least 18 year age If female , subject pregnant nursing Subject able provide write informed consent comply requirement study protocol . Chronic ( &gt; 6 month ) atopic dermatitis ( intrinsic disease IgE level 200 , extrinsic disease IgE level 200 ) . Moderate severe AD ( SCORAD index ≥25 , IGA index≥3 ) . Subjects woman childbearing potential must negative urine pregnancy test screening must practice adequate , medically acceptable method birth control least 30 day Day 0 least 6 month last study drug administration . Acceptable method birth control include intrauterine device ( IUD ) ; oral , transdermal , implanted inject hormonal contraceptive ( must initiate least 1 month enter study ) ; tubal ligation ; abstinence barrier method spermicide . Otherwise , childbearing potential , subject must : sterile vasectomized partner ; hysterectomy , bilateral oophorectomy clinically diagnose infertile ; menopausal state least year . Tuberculin purify protein derivative ( PPD ) QuantiFERON TBGold test ( QFT ) negative time screening , patient history positive PPD QuantiFERON , he/she complete appropriate prophylaxis . Subject judge good general health determine principal investigator base upon result medical history , laboratory profile , physical examination . Patients stable chronic asthma , treat inhaled corticosteroid , allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>extrinsic atopic dermatitis</keyword>
	<keyword>intrinsic atopic dermatitis</keyword>
</DOC>